Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in Dallas, Texas. It focuses on advancing FB102, a proprietary anti-CD122 monoclonal antibody candidate targeting autoimmune and related indications such as vitiligo and celiac disease.
As of August 2026, the company is subject to a pending acquisition by argenx through a cash tender offer at $77 per share, representing an equity value of approximately $2.2 billion. The transaction, announced in July 2026 and expected to close in Q3 2026, remains subject to customary conditions including regulatory approvals.
Official website: fortebiorx.com
